Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I-PRECISE: Ivonescimab Consolidation After SBRT for Early-Stage NSCLC
NCT07594522Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2026
- Primary completion
- May 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in non-small cell lung cancer (NSCLC), sponsored by Memorial Sloan Kettering Cancer Center. Started May 2026; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07594522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07594522.